Neuroone Medical Technologies Corp
NASDAQ:NMTC
Intrinsic Value
NeuroOne Medical Technologies Corp. operates as a medical technology company. [ Read More ]
The intrinsic value of one NMTC stock under the Base Case scenario is 0.213 USD. Compared to the current market price of 1.205 USD, Neuroone Medical Technologies Corp is Overvalued by 82%.
Valuation Backtest
Neuroone Medical Technologies Corp
Run backtest to discover the historical profit from buying and selling NMTC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Company Progresses With New FDA Clearance
2024-Q1 Earnings Call
The company received FDA clearance for its OneRF Ablation System and eyes a limited Q2 2024 launch, potentially via strategic partnerships or direct sales. Expansion in sales and successful Zimmer training suggest growth in Evo sEEG electrode revenue. Other initiatives like sEEG drug delivery could add revenue in late 2024, along with promising spinal cord stimulation studies. Q1 saw product revenue rise to $978,000 from $115,000, but no collaboration revenue, unlike last year's $1.455 million, increased net loss to $3.3 million from $1.7 million, with reduced cash reserves yet no debt.
Balance Sheet Decomposition
Neuroone Medical Technologies Corp
Current Assets | 5.1m |
Cash & Short-Term Investments | 2.7m |
Receivables | 543.4k |
Other Current Assets | 1.9m |
Non-Current Assets | 729.4k |
PP&E | 645.4k |
Intangibles | 84k |
Current Liabilities | 1.4m |
Accounts Payable | 760k |
Accrued Liabilities | 623.2k |
Non-Current Liabilities | 21k |
Other Non-Current Liabilities | 21k |
Earnings Waterfall
Neuroone Medical Technologies Corp
Revenue
|
2.9m
USD
|
Cost of Revenue
|
-2.1m
USD
|
Gross Profit
|
770.7k
USD
|
Operating Expenses
|
-14.3m
USD
|
Operating Income
|
-13.6m
USD
|
Other Expenses
|
95.2k
USD
|
Net Income
|
-13.5m
USD
|
Free Cash Flow Analysis
Neuroone Medical Technologies Corp
What is Free Cash Flow?
NMTC Profitability Score
Profitability Due Diligence
Neuroone Medical Technologies Corp's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Neuroone Medical Technologies Corp's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
NMTC Solvency Score
Solvency Due Diligence
Neuroone Medical Technologies Corp's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Neuroone Medical Technologies Corp's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NMTC Price Targets Summary
Neuroone Medical Technologies Corp
According to Wall Street analysts, the average 1-year price target for NMTC is 3.213 USD with a low forecast of 3.182 USD and a high forecast of 3.308 USD.
Ownership
NMTC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NMTC Price
Neuroone Medical Technologies Corp
Average Annual Return | -40.22% |
Standard Deviation of Annual Returns | 14.31% |
Max Drawdown | -96% |
Market Capitalization | 29.9m USD |
Shares Outstanding | 25 930 900 |
Percentage of Shares Shorted | 0.58% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeuroOne Medical Technologies Corp. operates as a medical technology company. The company is headquartered in Eden Prairie, Minnesota and currently employs 11 full-time employees. The company went IPO on 2012-11-09. The firm is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company also investigating the applications of its technology associated with artificial intelligence. The company develops its cortical, sheet and depth electrode technology to provides solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation and ablation. Its commercialized product, Evo sEEG electrode technology records, monitors and stimulates electrical signals at the subsurface level of the brain.
Contact
IPO
Employees
Officers
The intrinsic value of one NMTC stock under the Base Case scenario is 0.213 USD.
Compared to the current market price of 1.205 USD, Neuroone Medical Technologies Corp is Overvalued by 82%.